Business Progress - The company announced on February 11, 2026, that its subsidiary Tianxin Pharmaceutical and its branch Baiyunshan Pharmaceutical Factory have 24 products, including Cefuroxime Sodium for Injection, proposed for selection in the national drug procurement program. The total sales revenue for these products is projected to be 798 million yuan in 2024, accounting for 1.06% of the company's revenue, and 550 million yuan in the first three quarters of 2025, accounting for 0.89% of revenue [1]. Subsidiary Development - On February 2 and 3, 2026, subsidiaries Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. received changes to their drug production licenses from the Guangdong Provincial Drug Administration, involving new production addresses or adjustments to production workshops aimed at improving production efficiency. However, this is expected to have no significant impact on current financials [2]. Product R&D Progress - On February 6, 2026, the company's subsidiary Guangzhou Baiyunshan Xingqun Pharmaceutical Co., Ltd. successfully passed the consistency evaluation of quality and efficacy for its Alfacalcidol Soft Capsules, which are used to treat calcium metabolism disorders [3]. Funding Movements - According to data disclosed on February 5, 2026, JPMorgan Chase increased its holdings in Baiyunshan H-shares by 360,600 shares at approximately 18.85 HKD per share on January 30, 2026, raising its ownership stake to 9.12%. Additionally, the company emphasized in its Q3 2025 report that it would continue to promote its dividend policy and capital operations, but the timing of related events should be confirmed with the latest announcements [4].

Core Viewpoint - Guangzhou Pharmaceutical Group Co., Ltd. has disclosed significant anti-corruption results in a recent annual report, highlighting the company's commitment to integrity and governance [1] Group 1: Anti-Corruption Measures - The report details 17 cases of corruption over the past year, with a total amount involved of approximately 170 million yuan [1] - Internal sources indicate that these cases have been communicated internally as warnings to staff [1] Group 2: Disciplinary Actions - In 2025, the disciplinary inspection and supervision agencies of Guangzhou Pharmaceutical Group and its subsidiaries investigated 30 individuals and imposed 42 party disciplinary and administrative penalties [1] - The 17 typical cases involved key personnel from major subsidiaries, including Zhongyi Pharmaceutical, Wanglaoji Pharmaceutical, Baiyunshan Pharmaceutical Factory, He Jigong Pharmaceutical Factory, and Huanhong Traditional Chinese Medicine [1]

重要提醒！！！为防失联，请"星标"我们！进入无冕财经公众号，点击右上角"..."，再" "，以便您及时接收每篇推送~ wumiancaijing.com 最热的泛财经新闻，都在这儿了。 2月12日，广药集团纪律检查委员会发布文件，集中通报去年17起严重违纪违法典型案例，其中包括此前备受关注的广药集团腐败"窝案"。 文件通报的17起要案中，涉及广药集团旗下中一药业、王老吉药业、白云山制药总厂、何济公制药厂等多家核心子公司，涉案人职位上到董事长、总经 理、副总经理、部门总监、经理等各级管理人员，下至保卫科科长。腐败行为集中在药品原材料及包装材料采购、药品代理经销、广告投放与业务承揽、 款项结算、职务晋升等关键领域，部分人员还存在依托他人职权谋取私利、销售假药等严重违法行为，涉案总金额超2亿元。 ▲图片来自网络。 资讯整理：小冕 编辑：陈涧 设计：岚昇 广药集团腐败窝案15人被判刑 涉案超2亿，李楚源处理结果未出 本文由无冕财经（wumiancaijing）整理发布 从已披露的结果看，已有15人因受贿罪或销售假药罪被判处有期徒刑。其中，王老吉药业是被点名频次最高的企业，违法违纪行为涉及广药集团和王老吉 药业广告与媒 ...

Company Developments - Baiyunshan announced that its subsidiary Tianxin Pharmaceutical and Baiyunshan Pharmaceutical Factory plan to participate in the national drug procurement for 24 products, with projected sales revenue of 798 million yuan in 2024, accounting for 1.06% of the company's revenue, and 550 million yuan in the first three quarters of 2025, accounting for 0.89% [2] - Baiyunshan's subsidiaries, Guangzhou Baiyunshan Qixing Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd., received production license changes from the Guangdong Provincial Drug Administration to enhance production capacity and efficiency, although no significant financial impact is expected in the current period [3] Product Development - Baiyunshan's subsidiary Guangzhou Baiyunshan Xingqun Pharmaceutical Co., Ltd. has successfully passed the consistency evaluation of quality and efficacy for its Alfacalcidol soft capsules, which are used to treat calcium metabolism disorders [4] Financial Movements - Morgan Stanley increased its stake in Baiyunshan H-shares by 360,600 shares at approximately 18.85 HKD per share on January 30, raising its ownership to 9.12% [5] - The company reported a year-on-year increase in revenue and net profit in its Q3 2025 report, emphasizing its ongoing dividend policy and capital operations [5]

上述通报显示，在此次通报的17人中，15人因受贿罪或销售假药罪被判处有期徒刑，刑期最高的为十二 年有期徒刑（方广宏），有2人涉嫌相关违法已受党纪政务处分，尚未提及判决结果。 责任编辑：何俊熹 2月12日消息，据报道，曾在2024年引发社会各界高度关注的广药集团反腐风波在近日终于有了结论。 中共广州医药集团有限公司（简称广药集团）纪律检查委员会近日公布了《穗药集纪2025》16号文件， 通报了广药集团2025年度一系列典型违纪违法案例，其中就包括2024年底引发社会各界高度关注的广药 集团腐败"窝案"，涉案人员包括广药集团原党委委员、副总经理张春波；广州王老吉药业股份有限公司 原总裁、董事长方广宏；广州王老吉药业股份有限公司营销中心常务副总经理赵敏等17人。 2月12日消息，据报道，曾在2024年引发社会各界高度关注的广药集团反腐风波在近日终于有了结论。 中共广州医药集团有限公司（简称广药集团）纪律检查委员会近日公布了《穗药集纪2025》16号文件， 通报了广药集团2025年度一系列典型违纪违法案例，其中就包括2024年底引发社会各界高度关注的广药 集团腐败"窝案"，涉案人员包括广药集团原党委委员、副总经理张春 ...

Group 1 - The core viewpoint of the article highlights the company's strategy to enhance the value of the Wanglaoji brand by expanding its distribution network and collaborating with major restaurant platforms [1] - The company is focusing on promoting bottled beverages and exploring new product lines, including original flavor herbal tea and various fruit-flavored juice products, to cultivate a second growth curve [1] - In the functional beverage segment, the company has launched Wanglaoji Flash Recharge Electrolyte Water, indicating its commitment to innovation in product offerings [1]

Core Viewpoint - The company announced its participation in the national organized procurement for the continuation of products from the first to eighth batches, aiming to secure contracts for 24 pharmaceutical products, including injectable Cefuroxime Sodium and Clindamycin Phosphate Injection [1] Group 1: Company Participation - The company’s subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., and its branch, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., are involved in the procurement process [1] - The products targeted for procurement include Cefuroxime Sodium Injection, Clindamycin Phosphate Injection, Mebendazole Tablets, and Amoxicillin Granules among others [1] Group 2: Procurement Details - The procurement is based on the demand reported by medical institutions for each enterprise's products, with the selection price gradient determining the volume ratio [1] - The procurement cycle will last from the actual execution date of the selection results until December 31, 2028 [1]

Core Viewpoint - The company announced that its subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its injectable penicillin sodium, indicating successful compliance with the consistency evaluation of generic drug quality and efficacy [1] Group 1 - The injectable penicillin sodium is approved in a dosage of 0.96g (1.6 million units) [1] - This medication is indicated for various infections caused by sensitive bacteria, including abscesses, bacteremia, pneumonia, and endocarditis [1]

Group 1 - The company, Baiyunshan, announced that its subsidiaries, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., participated in the national centralized procurement for the continuation of products whose agreements have expired [1] - A total of 24 products, including Cefuroxime Sodium Injection and Clindamycin Phosphate Injection, are proposed to be selected for this procurement, which is based on the demand reported by medical institutions [1] - The procurement cycle will last until December 31, 2028, starting from the actual execution date of the selected results [1] Group 2 - The total projected sales revenue for the selected products in 2024 is approximately RMB 798 million, accounting for 1.06% of the company's total revenue for that year [2] - For the first three quarters of 2025, the projected sales revenue is about RMB 550 million, representing 0.89% of the company's revenue during that period [2] - If contracts are signed and implemented, it will further increase product sales, enhance market share, and positively impact the company's brand image and future business development [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 關於部分藥品在國家組織集采藥品協議期滿品種接續採購中擬中選的公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 证券代码：600332 证券简称：白云山 公告编号：2026-008 广州白云山医药集团股份有限公司 关于部分药品在国家组织集采药品协议期满品种 接续采购中拟中选的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州白云山医药集团股份有限公司（以下简称"公司"）控股子 公司广州白云山天心制药股份有限公司（以下简称"天心制药"）及 分公司广州白云山医药集团股份有限公司白云山制药总厂（以下简称 "白 ...